Endogenous opioid peptide
Beta-neoendorphin
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for Beta-neoendorphin →Peptide directory
Find a peptide
Public profiles inside a larger governed registry
Search by peptide name, brand, or research code. Open a full evidence profile or the published sources available for a record still in development. Source publication does not mean a completed scientific appraisal.
The registry is an expanding catalog, not a complete list of every peptide. A missing public result does not mean no research exists.
Published profiles
Search profiles and sources
Endogenous protein
Betatrophin
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for Betatrophin →Endogenous opioid peptide
Big dynorphin
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for Big dynorphin →- Developing
Bivalirudin is a synthetic 20-residue peptide anticoagulant derived conceptually from the thrombin-binding properties of hirudin. Its N-terminal D-phenylalanine-containing sequence binds the catalytic site of thrombin while a C-terminal region engages thrombin’s fibrin-recognition exosite; thrombin can subsequently cleave the molecule, contributing to reversible inhibition. It acts directly on circulating and clot-bound thrombin without requiring antithrombin. The molecule is established in percutaneous coronary intervention, while use in extracorporeal membrane oxygenation, cardiopulmonary bypass, pediatric procedures, and other settings has a different and often off-label evidence and regulatory context.
Evidence and record details
Evidence integrity map
Human 1Preclinical 1Durable IDs 7Open signals 1- Publication state
- Published profile
- Verified source records
- 25 source records verified
- Chemistry record
- Chemistry record on file
- Regulatory entries
- 2 published regulatory entries
- Research questions
- No open questions documented
- Evidence review date
- No documented human review recorded
Source verification checks records; it does not itself approve scientific conclusions.
Bioactive peptide
Bombesin
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Bombesin →Dipeptide-derived proteasome inhibitor
Bortezomib
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Bortezomib →- Developing
Synthetic research peptide
BPC-157
BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence associated with gastric proteins. Experimental studies report effects on angiogenesis, nitric-oxide signaling, inflammatory pathways, and tissue repair, but the proposed mechanisms are not established as therapeutic mechanisms in humans.
Evidence and record details
Evidence integrity map
Human 4Preclinical 16Durable IDs 26Open signals 3- Publication state
- Published profile
- Verified source records
- 25 source records verified
- Chemistry record
- Chemistry record on file
- Regulatory entries
- 2 published regulatory entries
- Research questions
- 23 open research questions
- Evidence review date
- No documented human review recorded
Source verification checks records; it does not itself approve scientific conclusions.
Endogenous vasoactive peptide
Bradykinin
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Bradykinin →Research reference
Bradykinin-potentiating peptide 9a
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for Bradykinin-potentiating peptide 9a →- Emerging
Bremelanotide is a melanocortin receptor agonist peptide studied in sexual-desire disorders. The relevant clinical populations, outcome measures, and treatment settings must be distinguished from other melanocortin compounds.
Evidence and record details
Evidence integrity map
Human 0Preclinical 0Durable IDs 6Open signals 2- Publication state
- Published profile
- Verified source records
- 52 source records verified
- Chemistry record
- Chemistry record on file
- Regulatory entries
- 2 published regulatory entries
- Research questions
- No open questions documented
- Evidence review date
- No documented human review recorded
Source verification checks records; it does not itself approve scientific conclusions.
Research reference
Brevinin-1E
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for Brevinin-1E →Defensin-mimetic investigational compound
Brilacidin
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Brilacidin →Synthetic peptide
Bronchogen
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Bronchogen →Lipopeptide therapeutic
Bulevirtide
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Bulevirtide →GnRH analog
Buserelin
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for Buserelin →Endogenous peptide
C-peptide
Published sources available; full evidence profile in development.
1 published source records. Source publication does not imply scientific appraisal.
Open sources for C-peptide →Endogenous natriuretic peptide
C-type natriuretic peptide
Published sources available; full evidence profile in development.
1 published source records. Source publication does not imply scientific appraisal.
Open sources for C-type natriuretic peptide →Bioactive amphibian peptide
Caerulein
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Caerulein →
How the public directory relates to the 500-record Master Registry
master registry transparency
500 master records, with governance status shown explicitly
501
Master records
467
Governed records
34
Review-deferred
458
Peptide acquisition eligible
9
Governed comparators
The master registry has 467 governed identities from 501 records. 34 remain review-gated. Nine governed records are scientific comparators, leaving 458 peptide identities in the source acquisition cohort. Database reconciliation is a separate step. The 51 profiles shown on this directory are a represented public-profile subset, not the size of the master registry. All 51 public profiles on this render reconcile to governed peptide identities in that registry; unknown, duplicate, deferred, or comparator identities fail closed instead of appearing publicly.
Explore the full Master Registry →What the profile status labels mean
Evidence, chemistry, and regulatory counts include only records that crossed the relevant public-publication gate. A zero means none published in that lane—not that nothing is known. “No governed record published” is a publication-state disclosure; internal or pending material may exist without appearing in public counts. Source verification, editorial publication, and accountable scientific appraisal are distinct states; a source count alone does not approve a scientific conclusion.
Recently updated public records
When each public profile record was last changed — not clinical or scientific activity.